Vertex Pharmaceuticals (VRTX) Retained Earnings (2009 - 2026)

Vertex Pharmaceuticals' Retained Earnings history runs 18 years deep, the most recent figure standing at $14.6 billion for Q1 2026.

• On a quarterly basis, Retained Earnings rose 21326.43% year-over-year to $14.6 billion in Q1 2026; TTM through Mar 2026 was $14.6 billion, a 21326.43% increase from a year earlier, with the FY2025 full-year figure at $13.6 billion, up 10510.33% from the prior year.
• Retained Earnings advanced to $14.6 billion in Q1 2026 per VRTX's latest filing, from $13.6 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $14.6 billion in Q1 2026 and bottomed at -$64.5 million in Q3 2025.
• The 5-year median for Retained Earnings is $68.1 million (2025), against an average of $3.5 billion.
• Across the five-year window, Retained Earnings tumbled 1887.5% in 2023 and jumped 289893.33% in 2024, its largest moves.
• Year by year, Retained Earnings stood at $800000.0 in 2022, then tumbled by 1887.5% to -$14.3 million in 2023, then jumped by 993.71% to $127.8 million in 2024, then jumped by 10510.33% to $13.6 billion in 2025, then gained by 7.61% to $14.6 billion in 2026.
• Per Business Quant, the three latest VRTX Retained Earnings figures stand at $14.6 billion (Q1 2026), $13.6 billion (Q4 2025), and -$64.5 million (Q3 2025).